RecruitingPhase 1NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Sponsor

Bristol-Myers Squibb

Enrollment

336 participants

Start Date

Jun 9, 2022

Study Type

INTERVENTIONAL

Conditions

Mesothelioma

Summary

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This early-phase study is testing a new drug called MRTX1719 in people with solid tumors that have a specific genetic change — a missing copy of a gene called MTAP. This genetic deletion makes cancer cells vulnerable to a particular type of drug attack, and researchers want to see how safe and effective MRTX1719 is. **You may be eligible if...** - You have a confirmed solid tumor cancer with a homozygous deletion of the MTAP gene - Your cancer cannot be removed with surgery or has spread - You are 18 years or older - You are in relatively good physical condition (able to carry out light activities) - Your heart, liver, and kidneys are functioning adequately **You may NOT be eligible if...** - You have previously been treated with a PRMT5 or MAT2A inhibitor - You have active brain tumors or cancer spreading to the lining of the brain - You had significant bleeding or major surgery within the last 4 weeks - You have serious bowel or stomach conditions that prevent swallowing pills - You have significant heart problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMRTX1719

MRTX1719 is a potent PRMT5-MTA inhibitor. Specified dose on specified days

Locations(25)

Mayo Clinic

Phoenix, Arizona, United States

Sarah Cannon Research Institute (SCRI) - HealthONE Location

Denver, Colorado, United States

Rocky Mountain Cancer Centers, LLP - Oncology

Lone Tree, Colorado, United States

Mayo Clinic

Jacksonville, Florida, United States

Sarah Cannon Research Institute at Florida Cancer Specialists

Orlando, Florida, United States

Local Institution - 124

Chicago, Illinois, United States

Dana-Farber Cancer Institute

Brookline, Massachusetts, United States

Cancer and Hematology Centers of Western Michigan

Norton Shores, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Local Institution - 129

Mineola, New York, United States

David H Koch, Memorial Sloan Kettering Cancer Center

New York, New York, United States

New york cancer and blood specialists - Oncology

Port Jefferson Station, New York, United States

New york cancer and blood specialists - Oncology

Port Jefferson Station, New York, United States

University of North Carolina - Gastroenterology and Hepatology

Chapel Hill, North Carolina, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Vanderbilt - Ingram Cancer Center

Nashville, Tennessee, United States

Ut Southwestern

Dallas, Texas, United States

Texas Oncology - DFW

Fort Worth, Texas, United States

MDACC

Houston, Texas, United States

South Texas Accelerated Research Therapeutics

San Antonio, Texas, United States

Texas Oncology, P.A. - Oncology

Tyler, Texas, United States

Virginia Cancer Specialists, PC

Fairfax, Virginia, United States

Local Institution - 134

Seattle, Washington, United States

Local Institution - 108

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05245500

Related Trials

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

NCT044310241 location

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

Agnostic Therapy in Rare Solid Tumors

NCT066389318 locations

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

NCT019505721 location

Rapid Autopsy and Procurement of Cancer Tissue

NCT018513951 location